Purpose Mutations in the KCNJ13 gene are known to cause Leber's Congenital Amaurosis (LCA16), an inherited pediatric blindness. KCNJ13 gene encodes the Kir7.1 subunit protein which acts as a tetrameric inwardly rectifying potassium ion channel in the retinal pigment epithelium to maintain ionic homeostasis thereby allowing photoreceptors to encode visual information. We sought to determine if genetic approaches might be effective in treating blindness due to mutations in KCNJ13.
Methods
We developed patient-derived hiPSC-RPE carrying an autosomal recessive nonsense mutation in the KCNJ13 gene (c.158G>A, p.Trp53*). We performed biochemical and electrophysiology assays of Kir7.1 function. Both small molecule read-through drug and genetherapy approaches were tested using this disease-in-a-dish approach.
Results
We found that the LCA16 hiPSC-RPE had normal morphology but did not express a functional Kir7.1 channel and was unable to demonstrate normal physiology. Following readthrough drug treatment, the LCA16 hiPSC cells were hyperpolarized by 30 mV and Kir7.1 current was restored. Similarly, loss-of-function of Kir7.1 channel was circumvented by lentiviral gene delivery to the hiPSC-RPE cells. In either approach, Kir7.1 protein was expressing normally with restoration of membrane potential and Kir7.1 current.
Conclusion Loss-of-function mutation in Kir7.1 is a cause of LCA. Using either read-through therapy or gene augmentation, we rescued Kir7.1 channel function in patient-derived iPSC-RPE cells via a precision medicine approach. (p.Leu241Pro). 1; 2; 4 In addition, the compound heterozygous KCNJ13 pathogenic variants c.314 G>T (p.Ser105Ile) and c.655C>T (p.Gln219Ter) were shown to cause early-onset retinal dystrophy in an LCA patient. 3 An autosomal dominant KCNJ13 pathogenic variant, c.484C>T (p.Arg162Trp), causes the early-onset blindness called snowflake vitreoretinal degeneration (SVD OMIM-193230). 5 KCNJ13 encodes the inwardly rectifying potassium channel, Kir7.1, and it is expressed in several tissues. 6; 7 In the retina, Kir7.1 is localized exclusively in the apical processes of RPE, where it controls retinal function and health. 8; 9 The major contribution of the Kir7.1 channel is in supporting the glial function of the RPE cells as modeled by LaCour. 10 Light activation of photoreceptors reduces RPE extracellular K+ concentration from 5 mM to 2 mM. Conductance of the Kir7.1 channel is increased when extracellular K+ is decreased, and vice versa. 11 Thus, KCNJ13 loss-of-function mutations will directly impact K+ buffering of the tight subretinal space and thereby alter photoreceptor function. A non-functional Kir7.1 channel will cause a sustained RPE cell depolarization that lead to cell death as has been reported after Kcnj13 gene knock-out or suppression in mice. 9; 12 The role of the Kir7.1 channel in other organs remains to be elucidated, but to-date, all mutations show a single ophthalmologic phenotype of blindness. 13; 14 A loss-of-function in KCNJ13, as with other channelopathies, is a convenient gene therapy target compared to the dominant negative SVD variant that alters wild-type channel function. 15 Technical challenges include controlling the level of expression and to successfully translate, traffick and assemble the ion channel as a functional unit in the membrane. Similarly, misincorporation of an amino acid during the translation of a non-sense codon limits the likelihood that the synthesis of full-length protein with function will be the outcome. To address these challenges, we adopted two precision medicine approaches where we used patient-derived iPSC-RPE cells to model LCA16 and explore novel fast-track approaches to mutation-specific therapies.
MATERIALS AND METHODS

Ethical guidance
This study was approved by the University of Wisconsin-Madison's Institutional Review Board in accordance with federal regulations, state laws, and local and University policies.
Differentiation of hiPSC-RPE
Fibroblasts from two subjects were reprogrammed to induced pluripotent stem cells and cultured using established methods. [16] [17] [18] One of the subjects was a LCA16 patient with p.Trp53* autosomal recessive mutation in the KCNJ13 gene, and the second subject (a non-symptomatic family member) was heterozygous for this mutation. Both the wild type hiPSC cells and hfRPE cells used as controls in our experiment have been previously characterized in our laboratory. 18; 19 The hiPSC lines were differentiated to RPE using protocols described earlier. 17; 18; 20; 21 Briefly, hiPSCs were cultured either on mouse embryonic fibroblasts (MEFs) in iPS cell media (Dulbecco's modified Eagle's medium (DMEM): F12 (1:1), 20% Knockout Serum, 1% minimal essential medium (MEM) non-essential amino acids, 1% GlutaMAX, β-mercaptoethanol, 20 ng/ml FGF-2), or on Matrigel with mTeSR1 media. Cells were lifted enzymatically and grown as embryoid bodies (EBs) in iPS media without FGF-2, and at day 4, changed to neural induction media (NIM; DMEM:F12; 1% N2 supplement, 1% MEM non-essential amino acids, 1% L-Glutamine, 2 µg/ml Heparin), or in mTeSR1 and gradually transitioned to NIM by day 4. There were no differences observed in RPE differentiation between these two approaches. At day 7, free-floating EBs were plated on laminin-coated culture plates to continue differentiation as adherent culture. At day 16, the 3D neural structures were removed, and media was switched to retinal differentiation media (DMEM/F12 (3:1), 2% B27 supplement (without retinoic acid), 1% Antibiotic-Antimycotic). Remaining adhered cells were allowed to continue differentiation for an additional 45 days, followed by microdissection and passaging of pigmented RPE patches to obtain purified monolayers of RPE as described earlier. 21 
RT-PCR and Restriction Fragment Length Polymorphism (RFLP)
Total RNA was isolated from mature hiPSC-RPE cells from both patient and the carrier, wild type hiPSC-RPE, and hfRPE using the RNeasy kit according to manufacturer's instructions (Qiagen). The quality and the concentration of the isolated RNA was measured using a Nanodrop (ThermoFisher) and 200 ng of RNA was used for cDNA synthesis using the Superscript III first strand cDNA synthesis kit according to manufacturer's instructions 
Transmission Electron Microscopy
Monolayers of hiPSC-RPE on transwell inserts (Corning, Cat#3470) were fixed with a solution of 2.5% glutaraldehyde, 2.0% paraformaldehyde in 0.1M sodium phosphate buffer (PB), pH 7.4
for ~1 hr at room temperature (RT). Samples were rinsed five times for 5 min in 0.1M PB. The rinsed cultures were post-fixed in 1% Osmium Tetroxide (OsO4), 1% potassium ferrocyanide in PB for 1 h at RT. Following post-fixation, samples were rinsed in PB, as before, followed by 3 x 5 min rinses in distilled water to clear the phosphates. The samples were then stained en bloc in uranyl acetate for 2 h at RT and dehydrated using an ethanol series. The membrane was cut from the transwell support, placed in an aluminum weighing dish, transitioned in propylene oxide (PO) and allowed to polymerize in fresh PilyBed 812 (Polysciences Inc. Warrington, PA).
Ultrathin sections were prepared from these polymerized samples and processed before capturing and documenting the images with FEI CM120 transmission electron microscope mounted with AMT BioSprint12 (Advanced Microscopy Techniques, Corp. Woburn, MA) digital camera. All electron microscope images were subjected to morphometry analysis of mitochondria number and length of apical processes. Mitochondira were counted manually using a blind-fold approach. We used a 10 um^2 area of the image and manually counted number of mitochondria.
For apical processes, we used the ImageJ program to define length of each apical process. All data from at least seven different images were averaged in Excel (Microsoft Corp., Redmond, WA, USA).
Immunocytochemistry (ICC)
Transwell inserts with monolayer of hiPSC-RPE cells from either the patient or control were fixed as follows: the transwell membrane was cut out and fixed by immersing it in 4% paraformaldehyde in phosphate-buffered saline for 10 min in the dark. The membrane with cells was washed with chilled PBS twice and blocked for 2 h in blocking solution that contained 5% 
Western blotting
Protein was isolated from >60 day old hiPSC-RPE cells on transwells using Radioimmunoprecipitation assay (RIPA) lysis buffer (ThermoFisher) along with sonication and was processed as described previously. 1 The primary antibodies used for Western blotting were anti-Kir7. 
Phagocytosis Assay
The labelled POS (photoreceptor outer segments) were prepared as previously published and fed to hiPSC-RPE cells growing in transwells that had a transepithelial electrical resistance (TEER) of >150 Ω cm 2 . 16; 22 The cells were fed POS for either 4 h or 24 h after which any POS that had not been phagocytosed were removed by washing the cells 3 times with DMEM media.
The cells were incubated for 24 h or 6 da respectively before imaging. The images were captured and analyzed with NIS-Elements using a Nikon C2 confocal microscope (Nikon Instruments Inc., Mellville, NY).
hiPSC-RPE Transduction
Lentivirus, custom engineered to be devoid of pathogenic elements, and carrying KCNJ13 gene fused at N -terminal with green fluorescent protein (GFP) under the control of EF1a promoter, was generated by Cyagen Biosciences (Santa Clara, CA, USA) and used for transduction. 23 
9
LCA-16 hiPSC-RPE monolayer was infected with pLV-EF1α Kir7.1-GFP at an MOI of 200.
The cells were cultured for 4-5 days after infection then used for immunocytochemistry and Western blotting (as described above).
Electrophysiology
Standard whole cell patch clamp on hiPSC-RPE cells, transduced hiPSC-RPE or hiPSC-RPE treated with read-through drug NB84, with distinct apical processes were performed as described elsewhere. 1 Data acquisition and the holding potential parameters were controlled using the 
Statistical analysis
The statistical analysis was performed using Origin (version 9.1) with a two-tailed Student's ttest to assess the significant differences. P<0.05 was considered statistically significant. ANOVA and post hoc Tukey test were also used for multiple comparisons. The data are expressed as the means ± SEM.
RESULTS
Analysis of patient derived hiPSC-RPE cells, herein referred to as LCA16 hiPSC-RPE, showed normal RPE morphology, including a cobblestone appearance and pigmentation ( Fig. 1a and b) ,
and was identical to homozygous wild-type hiPSC (Fig. S1a) . DNA sequencing confirmed that the control cells were from a heterozygous carrier, herein referred to as control (Ctrl) hiPSC-RPE, while the LCA16 pathogenic variant cells were apparently homozygous for the mutation c.158G>A. The LCA16 hiPSC cells had a normal karyotype (Fig. 1c) confirming that there was no chromosomal abnormality that might affect cellular behavior or response to therapy. The mutation (c.158G>A) introduced a restriction site for Nhe1, enabling the mutant sequence to be identified in patient-specific hiPSC-RPE, further verifying the presence of an apparently homozygous mutation (Fig. 1d) . The control hiPSC-RPE cells were analyzed similarly and found to be carrying an undigested 1083 bp band and two digested bands, consistent with the genotype of the donor (Fig. 1d) compared to a single full length transcript band of 1083 bp found in both wild type unrelated hiPSC-RPE cells and commercially available hfRPE cells ( Fig. 1d right panel). We believe there was no nonsense-mediated decay in LCA16 hiPSC-RPE as transcript levels were comparable to those in both carrier and wild-type hiPSC-RPE ( Fig. S1c,   d ). There was no difference in the expression of RPE-specific genes between the two cell types ( Fig. 1e) . Thus, the patient-derived iPSC-RPE conformed to the genotype of inherited retinal dystrophy and, therefore, provided a source to establish disease-specific cellular model. 1
Kir7.1 channels are located within the highly specialized apical membrane processes of RPE 8; 9 . We therefore examined intactness of apical membrane structures through electron microscope image analysis. The hiPSC-RPE cells had a polarized structure, including intact basal membrane infoldings and elongated apical processes (ap) that measured 1.49 ± 0.05 µm in length in the control hiPSC-RPE and 1.50 ± 0.14 µm in length in the proband's hiPSC-RPE (P = 0.96, n = 7) ( Fig. 2a, c and Fig. S2) . The distribution and number of mitochondria (m) in the two cell lines appeared normal, averaging 8.4 ± 1.0 and 6.2 ± 0.8 in the control and LCA16
proband's hiPSC-RPE, respectively (P = 0.12, n = 6) ( Fig. 2a and b) . Pigment granules correctly distributed apically in both cell types. Kir7.1 protein expression was detected on the apical membrane of mature control hiPSC-RPE cells but not in LCA16 hiPSC-RPE cells ( Fig. 2d and   e ). Western blot analysis for the C-terminal end of the Kir7.1 protein revealed a complete lack of Kir7.1 protein in the LCA16 disease model, as opposed to other RPE proteins that showed equal expression between control hiPSC-RPE and LCA16 hiPSC-RPE (Fig. 2f) . The p.Trp53* locus is located within the second exon of the 3-exon KCNJ13 sequence. We have shown previously that a nonsense substitution at amino acid 53 results in a truncated protein product making the LCA16 patient hiPSC-RPE a null allele, with no Kir7.1 channel function. 1 One of the key physiological functions of RPE cells is the daily phagocytosis of the photoreceptor outer segment (POS), which contributes to the POS renewal process. To test whether the absence of normal Kir7.1 protein alters phagocytosis, we fed both control and LCA16 hiPSC-RPE cell cultures with fluorescently labeled photoreceptor outer segments (POS).
The cells were fed labeled POS for 4 h, and phagosome digestion by RPE cells was allowed for an additional 24 h. Control hiPSC-RPE showed a higher rate of phagosomal uptake than LCA16 patient hiPSC-RPE (169 ± 40 vs 66.5 ± 7.4, P = 0.04, n = 4) ( Fig. 3a, b and c) . In addition, when cells were fed with POS for 1 day and then allowed to process phagosomes for 6 days, the LCA16 hiPSC-RPE cells failed to digest POS (80.2 ± 11.1 vs 244.2 ± 27.6 counts within a 200 µm 2 field, P = 0.001, n = 4) ( Fig. S2) . This finding suggests that the fundus pigmentation observed in LCA16 patients is likely due to an inability to phagocytose POS normally, which therefore accumulate over time in the retinas of affected individuals.
By using differentiated hiPSC-RPE from an asymptomatic carrier family member that develop apical processes and localize Kir7.1 to the apical membrane, we were able to detect a small but measurable Kir7.1 current (-144.2 ± 51 pA) in control hiPSC-RPE cells. Normal function was confirmed by a 13-fold increase in Rb+ permeability (-1887.3 ± 589.6 pA, n = 5) ( Fig. 3d and f, similar to wild-type hiPSC Fig. S1b) , which is a specific property of the Kir7.1 channel. 1; 24 However, in LCA16 hiPSC-RPE cells, we did not detect any change in the current amplitude mediated by Rb+ conductance (-98.1 ± 15.7 pA & -99.6 ± 15.7 pA, n = 9) ( Fig. 3e   and f) . A direct comparison of both current amplitude (P = 0.0006 with Rb+) and cell membrane potential (-50.0 ± 5.1 vs -30.6 ± 3.7 mV, P = 0.0005; as shown in Fig. 3g ) supports our hypothesis that the cause of blindness is a nonfunctional Kir7.1 channel which depolarizes LCA16 hiPSC-RPE cells. This is similar to observations in an in vivo Kir7.1-deficient mouse model or an in vitro cell line exogenously expressing the human Trp53* Kir7.1 channel. 1; 9 We next assessed the functional consequences of the NB84-mediated read-through on Kir7.1 current in LCA16 hiPSC-RPE cells. Following treatment of the LCA16 hiPSC-RPE with 500 µM NB84, we obtained a measurable current of -94.3 ± 24.0 pA, which was enhanced 10fold upon the introduction of the permeant ion Rb+ (-1562.7 ± 546.7 pA, P = 0.005, n = 8; Fig.   4a and b) . A significant recovery of membrane potential from -30.6 ± 3.7 in the untreated cells to -56.3 ± 3.6 mV (P = 0.0001, n = 10; Fig. 4c ) in the NB84 treated cells further supports the potential of read-through drug therapy for restoring channel function. In a subgroup of cells, we noticed rescue in membrane potential without any significant change in current amplitude. One possible explanation for this finding is the heterogeneity in the incorporation of the near-cognate amino acid during Kir7.1 protein translation (Fig. S3) .
Endogenous Kir7.1 protein levels in the NB84 treated hiPSC-RPE were below the detection level of Western blots so we transfected CHO cells with a mutant Kir7.1-eGFP fusion construct to detect the formation of the full length protein. After treating these cells with NB84, full length protein in addition to truncated protein was detected on a Western blot and both membrane potential and current deficits were corrected ( Fig. 4d and Fig. S4) , demonstrating that NB84 potentiates the specific read-through of the recessive Trp53* mutation.
We designed a lentiviral vector with an N-terminal GFP fused to the wild-type human
Kir7.1 open reading frame under the control of the EF1a promoter, 25 which was subsequently used to infect hiPSC-RPE monolayers. Intriguingly, wild-type Kir7.1-expressing cells presented normal Kir7.1 currents or even slightly higher amplitudes than those observed in the control cells (-921 ± 223 pA, P = 0.001, n = 8). This current was further potentiated by the introduction of Rb+ (-5453 ± 929 pA), as expected for a normally functioning Kir7.1 channel ( Fig. 5a and b) . In addition to K+ currents, the membrane potential of LCA16 iPSC-RPE cells was approaching normal values (-57.5 ± 5.4 mV, P = 0.0008) ( Fig. 5c) . Moreover, newly expressed full length Kir7.1 (Fig. 5d ) was shown to be localized to the apical membranes of patient-specific hiPSC-RPE cells (Fig. 5e and Supple. Video) .
DISCUSSION
We have reported previously that targeted inhibition of Kir7.1 in the mouse retina (induced using either siRNA or a pharmacological blocker) causes an altered electroretinogram phenotype consistent with that observed in LCA16 patients. 9 In the current report, we extend our findings by describing the development of a novel LCA16 disease-in-a-dish model. We developed a robust hiPSC-RPE cell culture derived from skin biopsies from one LCA16 proband carrying an apparently homozygous nonsense mutation in exon 2 of the KCNJ13 gene (p.Trp53*) and a control from an unaffected healthy family member. 16 The highly pigmented RPE cells from both control and patient appeared normal, expressed RPE markers and were immunopositive for several RPE specific proteins except the LCA16 hiPSC-RPE lacked mutation-specific Kir7.1 protein expression. Rescue of Kir7.1 function in RPE cells shown by us is an intervention that could improve vision in patients with congenital blindness due to KCNJ13 mutations.
Our study determined that the major pathogenic alteration affecting the RPE cells is the lack of functional Kir7.1 channel. We were also able to establish a genotype-phenotype (normal) correlation in an asymptomatic carrier individual suggesting complete penetrance of p.Trp53* pathological mutation. Use of carrier (control) hiPSC-RPE, from within the family, also accounts for action of modifier genes, epigenetic changes or environmental contribution. We have previously determined that cultured human fetal RPE cells express Rb+ sensitive Kir7.1 current similar to what we recorded from wild-type and carrier hiPSC-RPE cells. 19 In our hands, heterozygous expression of equal amounts of wild type and non-functional p.Trp53* mutant protein also does not influence cellular physiology outcome. 1 Given these findings, we reasoned that carrier hiPSC-RPE are a suitable control to compare test results of both gene restoration and translational read-through.
Our diseased hiPSC-RPE model is particularly valuable given that a Kcnj13 gene knock out in mice has been proven to cause embryonic lethality suggesting that there is a different function of Kcnj13 gene in mice or animal models that complicates the study of disease pathobiology. 12; 26; 27 We showed that patient-specific hiPSC-RPE cells had normal apical processes where Kir7.1 protein is expressed. We thus confirmed maturity of these cultured hiPSC-RPE cells unlike the ones generated from ciliopathy patients. 28 Matured LCA16 hiPSC-RPE cells did not show Kir7.1 function, their membrane potential was depolarized and they were unable to phagocytose photoreceptor outer segments as compared to control hiPSC-RPE cells. A defect in the phagocytosis of shed photoreceptor outer segments by LCA16 hiPSC-RPE is thus secondary and consistent with the slow progression toward blindness observed in LCA16 patients, as documented through clinical manifestations, including electroretinogram abnormalities and retinal pigmentation. [1] [2] [3] [4] In general, it is challenging to study ion-channels in iPSCs due to the lack or low level of expression but we have used the powerful tool of stem cell technology to analyze the pathophysiology of LCA16. 29 The LCA16 mutation p.Trp53* analyzed in this report is a tryptophan (UGG) to amber (UAG) stop codon variant. 1 An in-frame nonsense mutation accounts for about 12% of inherited genetic disorder. 30 Several studies have demonstrated the usefulness of read-through therapy as an intervention that could improve vision. [31] [32] [33] Designer aminoglycosides such as NB84 bind to eukaryotic ribosomal RNA decoding site. 34 This binding promotes the transition of the 16S rRNA decoding center from a tRNA binding conformation to a productive state resulting in an increase in the rate of read through at a stop codon. 35 . Here we show that a KCNJ13 p.Trp53* nonsense mutation is suppressed by the incorporation of a near-cognate aminoacyl tRNA in the presence of the small-molecule read-through designer aminoglycoside NB84. 33; 36; 37 Aminoglycosides pose toxicity concerns in the adult, but both in vitro and in vivo toxicity studies demonstrate that NB84 is ready for translational therapy in animal models and human subjects. 38 We foresee further development of a non-toxic formulation of NB84 (Poly-L-aspartate that increases cytoplasmic concentration 39 ) for topical application to eye so that risks to other organs are avoided. As expected, only a fraction of cells showed complete recovery of both membrane potential and current amplitude whereas there was a subgroup with partial recovery of function.
Read-through therapy also has a significant clinical advantage in the management of LCA16 at an early stage when diagnosed.
The particular mutation studied herein, and other recessive mutations that cause blindness, are potential targets for gene therapy. This premise is nearing reality given the recent FDA approval of a gene therapy treatment for blindness. 40,41; 42 Using a LCA16 hiPSC-RPE model, we demonstrate that the rescue of channelopathy via lentiviral gene augmentation produced a potassium current and normalized membrane potential (Fig. S5) . Newly expressed protein was also localized to apical aspects of LCA16 hiPSC RPE cells.
Gene therapy is a very simple concept but the problem remains that too little or too much of the expression will have deleterious effects. 43; 44 To understand an optimum dosing required in our case, we expressed copies of both wildtype and mutant protein in a heterologous expression system. We observed that as little as 25% of wildtype protein expression of total Kir7.1 protein product was sufficient to enhance both membrane potential as well as potassium current and rescued the mutant phenotype (Fig. S6) . A splice variant of Kir7.1 was reported in human RPE cells which failed to produce anticipated small protein band. 45 Furthermore, the expected truncated protein consisted of N-terminus and the first transmembrane domain so the LCA16 nonsense mutation p.TRP53W* is predicted to truncate all Kir7.1 transcript variants. The p.Trp53* truncated protein product does not assemble with wild type protein to alter Kir7.1 channel function and does not perhaps undergo nonsense-mediated decay as a truncated protein product is expressed after heterologous expression. 1 In this study we have taken advantage of long lasting transgene expression in RPE cells in vivo through Lentivirus transduction. 46 Also, AAV in our hand was unable to transduce iPSC-RPE cells as has been experienced by several other groups. This might be due to the higher efficacy of lentiviral vector to transduce post mitotic RPE cells as has been proved for nondividing cells. 47 Our 3 rd -generation lentivirus packaging system also has reduced risk of generating replication-competent virus. In a preclinical study carried out in non-human primate, subretinal delivery of lentiviral RPE65 gene showed that the vector stayed in the eye perhaps because of the tight blood-retina barrier with high systemic safety. 48 Retinal gene therapy using lentiviral vector is in clinical trials for Neovascular age-related macular degeneration, Stargardt disease, and Usher syndrome type 1B. 49 We conclude that both treatments developed in this study are able to achieve at least 25% normal protein expression as restoration of membrane potential was complete with variable recovery in current amplitude. Achieving this 25% functional rescue in vivo will thus be less challenging and mutant protein product will not influence functional outcome.
Advances in genetic screening and improvements in access to medical care will undoubtedly improve our understanding of the array of disorders caused by channelopathies and expand our understanding of the role that KCNJ13 plays in health and disease. Genome editing holds promise for genetic disorders but gene correction in non-dividing cells and introduction of unwanted genomic variants at the target and off-target sites limits its potential use. Overall, we
show a promising proof of concept for read-through and gene-augmentation therapy using a precision medicine approach that would benefit pediatric blindness (LCA16) patients.
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